176 related articles for article (PubMed ID: 34975010)
21. Prognostic significance of CEBPA mutations and BAALC expression in acute myeloid leukemia Egyptian patients with normal karyotype.
El-Sharnouby JA; Ahmed LM; Taha AM; Kamal O
Egypt J Immunol; 2008; 15(1):131-43. PubMed ID: 20306678
[TBL] [Abstract][Full Text] [Related]
22. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
[TBL] [Abstract][Full Text] [Related]
23. [CEBPA gene mutation analysis in acute myeloid leukemia].
Han C; Lin D; Ai XF; Wang F; Sun HY; Wang M; Mi YC; Wang JX; Ru K
Zhonghua Xue Ye Xue Za Zhi; 2013 Jul; 34(7):566-71. PubMed ID: 23906447
[TBL] [Abstract][Full Text] [Related]
24. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
Braun TP; Okhovat M; Coblentz C; Carratt SA; Foley A; Schonrock Z; Curtiss BM; Nevonen K; Davis B; Garcia B; LaTocha D; Weeder BR; Grzadkowski MR; Estabrook JC; Manning HG; Watanabe-Smith K; Jeng S; Smith JL; Leonti AR; Ries RE; McWeeney S; Di Genua C; Drissen R; Nerlov C; Meshinchi S; Carbone L; Druker BJ; Maxson JE
Nat Commun; 2019 Nov; 10(1):5455. PubMed ID: 31784538
[TBL] [Abstract][Full Text] [Related]
25. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
26. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Maxson JE; Ries RE; Wang YC; Gerbing RB; Kolb EA; Thompson SL; Guidry Auvil JM; Marra MA; Ma Y; Zong Z; Mungall AJ; Moore R; Long W; Gesuwan P; Davidsen TM; Hermida LC; Hughes SB; Farrar JE; Radich JP; Smith MA; Gerhard DS; Gamis AS; Alonzo TA; Meshinchi S
Blood; 2016 Jun; 127(24):3094-8. PubMed ID: 27143256
[No Abstract] [Full Text] [Related]
27. Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Matsuo H; Kajihara M; Tomizawa D; Watanabe T; Saito AM; Fujimoto J; Horibe K; Kodama K; Tokumasu M; Itoh H; Nakayama H; Kinoshita A; Taga T; Tawa A; Taki T; Tanaka S; Adachi S
Blood Cancer J; 2014 Jul; 4(7):e226. PubMed ID: 25014773
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia.
Wakita S; Sakaguchi M; Oh I; Kako S; Toya T; Najima Y; Doki N; Kanda J; Kuroda J; Mori S; Satake A; Usuki K; Ueki T; Uoshima N; Kobayashi Y; Kawata E; Tajika K; Nagao Y; Shono K; Shibusawa M; Tadokoro J; Kayamori K; Hagihara M; Uchiyama H; Uchida N; Kubota Y; Kimura S; Nagoshi H; Ichinohe T; Kurosawa S; Motomura S; Hashimoto A; Muto H; Sato E; Ogata M; Mitsuhashi K; Ando J; Marumo A; Omori I; Fujiwara Y; Terada K; Yui S; Arai K; Kitano T; Miyata M; Kurosawa A; Mizoguchi A; Komatsu N; Fukuda T; Ohashi K; Kanda Y; Inokuchi K; Yamaguchi H
Blood Adv; 2022 Jan; 6(1):238-247. PubMed ID: 34448807
[TBL] [Abstract][Full Text] [Related]
29. Clinical Significance of bZIP In-Frame CEBPA-Mutated Normal Karyotype Acute Myeloid Leukemia.
Ahn SY; Kim T; Kim M; Song GY; Jung SH; Yang DH; Lee JJ; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Kim HJ; Ahn JS; Kim DDH
Cancer Res Treat; 2023 Jul; 55(3):1011-1022. PubMed ID: 36701843
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
31. Favorable prognosis of biallelic CEBPA gene mutations in acute myeloid leukemia patients: a meta-analysis.
Li HY; Deng DH; Huang Y; Ye FH; Huang LL; Xiao Q; Zhang B; Ye BB; Lai YR; Mo ZN; Liu ZF
Eur J Haematol; 2015 May; 94(5):439-48. PubMed ID: 25227715
[TBL] [Abstract][Full Text] [Related]
32. Companion gene mutations and their clinical significance in AML with double or single mutant CEBPA.
He J; Liu J; Shen H; Wang Z; Cao L; Wu P; Chao H; Lu X; Jia Z; Chen M; Cai X
Int J Hematol; 2022 Jul; 116(1):71-80. PubMed ID: 35314954
[TBL] [Abstract][Full Text] [Related]
33. GATA2 mutations in patients with acute myeloid leukemia-paired samples analyses show that the mutation is unstable during disease evolution.
Hou HA; Lin YC; Kuo YY; Chou WC; Lin CC; Liu CY; Chen CY; Lin LI; Tseng MH; Huang CF; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Chen YC; Tien HF
Ann Hematol; 2015 Feb; 94(2):211-21. PubMed ID: 25241285
[TBL] [Abstract][Full Text] [Related]
34. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
Mendoza H; Podoltsev NA; Siddon AJ
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
[TBL] [Abstract][Full Text] [Related]
35. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
Kim SY; Song IC; Kim J; Kwon GC
Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470
[TBL] [Abstract][Full Text] [Related]
36. Mutational spectrum of acute myeloid leukemia patients with double
Su L; Tan Y; Lin H; Liu X; Yu L; Yang Y; Liu S; Bai O; Yang Y; Jin F; Sun J; Liu C; Liu Q; Gao S; Li W
Oncotarget; 2018 May; 9(38):24970-24979. PubMed ID: 29861846
[TBL] [Abstract][Full Text] [Related]
37. Familial CEBPA-mutated acute myeloid leukemia.
Tawana K; Rio-Machin A; Preudhomme C; Fitzgibbon J
Semin Hematol; 2017 Apr; 54(2):87-93. PubMed ID: 28637622
[TBL] [Abstract][Full Text] [Related]
38. A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia.
Marcolin R; Guolo F; Minetto P; Clavio M; Manconi L; Ballerini F; Carli A; Passannante M; Colombo N; Carminati E; Pugliese G; Tedone E; Contini P; Mangerini R; Kunkl A; Miglino M; Cagnetta A; Cea M; Gobbi M; Lemoli RM
Leuk Res; 2019 Nov; 86():106223. PubMed ID: 31557597
[TBL] [Abstract][Full Text] [Related]
39. Deficient CEBPA DNA binding function in normal karyotype AML patients is associated with favorable prognosis.
Fos J; Pabst T; Petkovic V; Ratschiller D; Mueller BU
Blood; 2011 May; 117(18):4881-4. PubMed ID: 21389317
[TBL] [Abstract][Full Text] [Related]
40. [NPM1 and CEBPA mutations in pediatric cytogenetically normal acute myeloid leukemia].
Ruan M; Zhang L; Han C; Liu X; Ai X; Zhang J; Liu T; Yang W; Chen X; Guo Y; Wang S; Li Q; Zou Y; Chen Y; Zhu X
Zhonghua Er Ke Za Zhi; 2014 Apr; 52(4):303-7. PubMed ID: 24915920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
